House Bill 553 revises North Carolina’s laws governing abortion-inducing drugs, with a particular focus on mail-order, shipping, advertising, and other remote distribution of those drugs. The bill makes it unlawful for individuals, physicians, clinics, manufacturers, suppliers, or organizations to mail, provide, supply, ship, or promote abortion-inducing drugs to a pregnant woman in North Carolina when the drugs would be administered outside the physical presence of a physician, unless specified conditions are met. Those conditions include an in-person informed-consent meeting at least 72 hours in advance, satisfaction of most existing informed-consent requirements, and use of FDA-approved drugs.
The bill also targets internet-based promotion and procurement of abortion-inducing drugs directed at pregnant North Carolina residents when the purpose is to facilitate administration in violation of the bill’s requirements. It creates civil enforcement mechanisms allowing an injured woman, a parent or guardian of a minor, or the Attorney General to sue, and it authorizes injunctive relief, compensatory and punitive damages, and attorneys’ fees. The bill further provides that foreign entities involved in shipping or procuring abortion-inducing drugs into the state are deemed to be conducting business in North Carolina and must obtain and maintain a certificate of authority, expanding the state’s jurisdiction over those entities.
As drafted, the bill would amend G.S. 14-44.1 and related provisions, and it would make violations a Class H felony rather than an infraction with a $5,000 fine. It also sets a three-year limitations period for civil actions and includes special timing rules for minors. The effective date for the substantive changes is December 1, 2025, applying to offenses committed on or after that date.
Because there are no committee transcripts or recorded votes in the provided materials, there is no direct evidence of legislative debate or formal support/opposition in the record here. Based on the bill text and title, the measure appears to be framed as a patient-safety and informed-consent bill, but it is substantively a significant restriction on medication abortion access and on mail-order abortion-drug distribution. The main points of likely contention are the criminalization of conduct, the expanded civil liability scheme, the regulation of online advertising and foreign entities, and the requirement for in-person physician involvement before mailing or supplying the drugs.
The bill would substantially tighten North Carolina law on abortion-inducing drugs by prohibiting or limiting mail-order, direct-to-patient, and internet-facilitated distribution unless strict informed-consent and FDA-approval conditions are met. It would amend G.S. 14-44.1, create new civil causes of action and remedies, and increase the penalty for violations to a Class H felony. It also extends state regulatory reach to out-of-state entities shipping or procuring abortion-inducing drugs into North Carolina by requiring certificates of authority and subjecting them to personal jurisdiction in state courts.
No committee discussion or vote history was provided, so there is no documented legislative sentiment in the record beyond the bill’s text and title. The title emphasizes patient safety, suggesting supporters would frame the measure as an informed-consent and safety regulation. The substance of the bill, however, indicates it would be viewed by opponents as a major abortion restriction, so the overall sentiment is likely polarized and closely aligned with broader abortion-policy divisions.
The most likely points of contention are the bill’s requirement for in-person physician counseling 72 hours before mailing or supplying abortion-inducing drugs, the prohibition on direct-to-patient shipment absent those conditions, and the criminal penalty increase to a felony. Opponents would likely object to the civil enforcement structure, including private lawsuits by women, parents, guardians, and spouses, as well as the broad reach over websites, advertisements, and foreign entities. Supporters would likely argue the bill improves safety, informed consent, and accountability for medication abortion distribution.